Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: M09AX02

ChondroCelect(characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins)

Cartilage Diseases

Marketing Authorisation Holder: TiGenix N.V.

EMA Authorisation: 05/10/2009

INN: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

Indication

Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults. Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about ChondroCelect — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.